跳至主要内容
临床试验/NCT07451158
NCT07451158进行中(未招募)不适用

Multicenter, Double-blind, and Randomized Controlled Trial of Ultra-Distal Transcutaneous Electrical Nerve Stimulation (TENS) Device for Migraine Treatment

Second Affiliated Hospital, School of Medicine, Zhejiang University1 个研究点 分布在 1 个国家目标入组 206 人开始时间: 2025年11月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
206
试验地点
1
主要终点
Reduce the intensity of migraine

研究概览

简要总结

Multicenter, double-blind, and randomized controlled trial of Ultra-Distal Transcutaneous Electrical Nerve Stimulation (TENS) Device for Migraine treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female, aged between 18 and 75;
  • According to the diagnostic criteria of the International Classification of Headache Disorders (ICHD-III), the diagnosis is episodic migraine with or without aura or probable migraine with or without aura;
  • The duration of the illness is at least 12 months;
  • The age of onset of the first migraine is less than 50 years old;
  • During the screening period of 4 weeks, there were 2-8 episodes of headache, with moderate or severe pain intensity;
  • Before screening, the subjects should provide their previous medical records as much as possible;
  • Participants can distinguish migraines from other conditions, including tension-type headaches and cluster headaches
  • Understand and adhere to the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing;

排除标准

  • Pregnant and lactating women;
  • Suffering from arrhythmia or other heart diseases (such as ischemic heart disease, coronary artery spasm, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, angina pectoris);
  • Have undergone surgery within the past 6 months;
  • Recent stroke or transient ischemic attack;
  • Equipped with a pacemaker;
  • History of previous seizures;
  • Metal implants in the head;
  • Patients with clinical evidence of brain damage;
  • Chronic pain associated with other diseases;
  • Use antipsychotic drugs;
  • Those who are intolerant to neuroregulators;
  • Employees of the research center or their immediate family members.
  • There is a condition or anomaly that the investigator believes may affect patient safety or data quality

研究组 & 干预措施

Group B

Placebo Comparator

Fake Stimulus Group

干预措施: Fake Stimulus (Device)

Group A

Experimental

Transcetaneous Electrical Stimulation

干预措施: Trail of Ultral-distal Transcutaneous Electrical Nerve Stimulation (Device)

结局指标

主要结局

Reduce the intensity of migraine

时间窗: Baseline and 2 hours post-treatment

After treatment, participants rated their headache intensity as 0 (no pain =0 points, mild =1 point, moderate =2 points, severe =3 points).

the pre-selected accompanying symptoms

时间窗: Baseline and 2 hours post-treatment

Participants no longer experienced the pre-selected accompanying symptoms (e.g., nausea, vomiting, photophobia, phonophobia) after 2 hours of treatment.

次要结局

  • pain relief(Baseline and 2 hours post-treatment)
  • returned to normal function(Baseline and 2 hours post-treatment)
  • Use of acute treatment drugs(Baseline and 24 hours post-treatment)
  • recurrence of migraine(Baseline and 2-24 hours post-treatment)
  • recurrence of migraine2(Baseline and 2-48 hours post-treatment)
  • pain-free status(Baseline and 15,30,45,60, and 90 minutes post-treatment)
  • symptoms free(Baseline and 15,30,45,60, and 90 minutes post-treatment)

研究者

发起方
Second Affiliated Hospital, School of Medicine, Zhejiang University
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验